found Documents: 413

Announcements & Press Releases, Group | 17 Nov 2020

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong, Shanghai, & Florham Park, NJ: Tuesday

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 5 Nov 2020

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be pre

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors

Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China

Chi-Med to Announce 2020 Half-Year Financial Results

Chi-Med Announces US$100 Million Equity Investment by General Atlantic

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program

Chi-Med to Attend Upcoming Investor Conferences

Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China

2019 Annual Report and Notice of Annual General Meeting

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

Chi-Med to Announce 2019 Final Results

Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

Chi-Med Announces Proposed Public Offering of ADSs

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference

Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

Chi-Med to Attend Upcoming Investor and Industry Conferences

Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting